At what enterprise value was SARQUAVITAE acquired in 2016?

During the acquisition of SARQUAVITAE by DOMUSVI in 2016, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SARQUAVITAE when it was acquired by DOMUSVI?

The estimated EV/EBITDA multiple for SARQUAVITAE is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was SARQUAVITAE acquired by DOMUSVI?

SARQUAVITAE was acquired by DOMUSVI in 2016.

What was the revenue of SARQUAVITAE at the time of the deal?

The revenue of SARQUAVITAE at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of SARQUAVITAE during the acquisition?

SARQUAVITAE's EBITDA is estimated to be in the range of 25M - 50M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SARQUAVITAE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SARQUAVITAE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.pemagazine.fr/nti1mw-excellente-sante-financiere-pour-domusvi/

← DATABASE

Home Database Healthcare & PharmaSARQUAVITAE

10/2016

SARQUAVITAE acquired by DOMUSVI

SPAIN Health Providers / Healthcare Facilities / Nursing Homes EV 300M - 700M EUR

Context

DomusVi has successfully acquired its Spanish competitor SARquavitae, previously held by a consortium of investment funds including Palamon Capital Partners and G Square Capital. This transformative build-up operation allows the group to become the number one player in the Spanish elderly care market. The strategic rationale centers on geographic diversification, as the target’s strong footprint in Catalonia and Madrid perfectly complements the acquirer’s existing position in Galicia. The integration adds 88 facilities and 11,000 beds to the group’s portfolio, bringing total pro forma revenues to approximately €1.2 billion. This acquisition marks a significant milestone in the group’s international expansion strategy, following the previous year’s integration of another Spanish operator, thereby solidifying its leadership position in Southern Europe.

SARQUAVITAE, which reported an EBITDA margin of LOGIN in 2016, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

SARquavitae is a leading Spanish provider of elderly care services, operating an extensive network of 88 facilities with a total capacity of 11,000 beds. The entity maintains a particularly strong strategic presence in key regions including Catalonia and Madrid, complementing its historical operations. Its business model focuses on residential care and specialized medical services for the dependent elderly population. The company provides high-quality clinical and hospitality services, positioning itself as a primary competitor in the Iberian long-term care market. By integrating advanced healthcare management protocols, the group ensures a stable value proposition for both private residents and public regional healthcare systems. The organization has demonstrated consistent growth and operational stability, making it a pivotal asset for consolidation in the European healthcare infrastructure landscape.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2017	EQT PARTNERS	COLISÉE	FRANCE	Health Providers	IK Investment Partners, through its IK VIII Fund, reached an agreement with Eurazeo PME and the management team to acquire a majority stake in Colisée. The founding family and management team reinvested alongside IK, ensuring continuity of strategic direction and operational leadership
01/2017	PARTNERS GROUP / PSP INVESTMENTS	CERBA HEALTHCARE	FRANCE	Health Providers	Partners Group and Canadian pension fund PSP entered exclusive negotiations to acquire Cerba from PAI Partners. The consortium beat out CVC and Apax, but most notably rejected a higher offer (>EUR2bn) from industrial player Cinven (owner of Synlab/Labco)
03/2016	F2I SGR / CIR - COMPAGNIE INDUSTRIALI RIUNITE	KOS GROUP	ITALY	Health Providers	CIR and F2i have signed an agreement to acquire the 46.7% stake in KOS Group previously held by Ardian. The strategic rationale for the transaction is to resolve the future ownership structure of the group, allowing CIR to maintain long-term industrial control while enabling Ardian to exit after a six-year investment cycle
08/2015	CINVEN	SYNLAB	GERMANY	Health Providers	The acquisition of Synlab by Cinven from BC Partners represents a landmark transaction in the European healthcare services sector, following closely on the heels of Cinven’s acquisition of the French group Labco
07/2015	ANTIN INFRASTRUCTURE	AMEDES	GERMANY	Health Providers	Antin Infrastructure Partners acquired a majority stake in Amedes Group from General Atlantic. The transaction provided an exit for General Atlantic, which had owned the asset since 2007 and tripled its revenues through a buy-and-build strategy (30+ acquisitions)
05/2015	CINVEN	LABCO	FRANCE	Health Providers	The acquisition of Labco by funds managed by Cinven follows the strategic withdrawal of the company’s planned Initial Public Offering (IPO) on Euronext Paris. This transaction allowed for the total rationalization of a complex shareholding structure previously split between financial investors (3i, TCR Capital, NiXen, CM-CIC), founders, and a large group of independent biologists
01/2015	CERBA HEALTHCARE	NOVESCIA	FRANCE	Health Providers	Cerba acquired 100% of Novescia. The seller was a complex consortium managed by Ekkio Capital, including financial investors Cobepa and Socadif, as well as biologist shareholders. This acquisition allowed Cerba to reach critical mass in the routine segment, complementing its leadership in specialty testing
10/2014	WATERLAND	MEDIAN KLINIKEN	GERMANY	Health Providers	Waterland Private Equity agreed to acquire 100% of MEDIAN Kliniken from Advent International and British real estate investor Marcol. Concurrently with the acquisition, Waterland announced its intention to sell MEDIAN's real estate portfolio through a sale-and-leaseback arrangement with a US real estate investor over the following months, effectively separating the operational business from its property assets
09/2014	EURAZEO	COLISÉE	FRANCE	Health Providers	The acquisition of Groupe Colisée by Eurazeo PME is a strategic move that aligns with the firm's investment strategy of supporting companies that are well-positioned to benefit from underlying societal trends
06/2014	PAI PARTNERS	DOMUSVI	FRANCE	Health Providers	PAI Partners has entered into exclusive negotiations to take control of DomusVi, the third largest French player in the private nursing home sector. Upon completion of the transaction, PAI is expected to hold 70% of the capital alongside an associated fund

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SARQUAVITAE by DOMUSVI are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).